<p>TEL AVIV, Israel , April 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced that it has been awarded a grant of 8.9 million New Israeli Shekels (approximately $2.5 million ) by the Israel Innovation Authority (IIA).  The funds will support the development of the Company’s...

Conference Call and Webcast at 8:30am Eastern Time TEL AVIV, Israel , March 15, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced...

TEL AVIV, Israel , March 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

Conference Call and Webcast @ 8:30am ET Today TEL AVIV, Israel , March 08, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today reported top-line results from its pivotal Phase 3 GLOBE study in patients with recurrent glioblastoma (rGBM) which was designed to evaluate VB-111 in...

- Per agreement, milestone payments can exceed $100 million , in addition to double-digit million tiered royalties - TEL AVIV, Israel , Feb. 08, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announces that it has received a milestone payment from  NanoCarrier Co., Ltd....

Senior pharmaceutical executives with extensive experience in immuno-oncology, drug development, commercializing oncology medications and finance TEL AVIV, Israel , Jan. 03, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced the appointments of both David Hastings and Susan...

TEL AVIV, Israel , Dec. 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced the study initiation and first patient in its Phase 3 pivotal registration trial, OVAL, studying its lead candidate VB-111 (ofranergene obadenovec) in platinum-resistant ovarian cancer....

TEL AVIV, Israel , Dec. 18, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), announced new biomarker data supporting the direct link between lead asset VB-111’s dual mechanism of action and clinical effect on overall survival (OS) and progression-free survival (PFS) in patients from the...

TEL AVIV, Israel , Nov. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate overview via a Fireside Chat...

TEL AVIV, Israel , Nov. 17, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced the pricing of its previously announced underwritten...